COVID-19 and a Tale of Three Drugs: To Repurpose, or Not to Repurpose-That Was the Question

Area of Science:

• * Infectious Diseases and Virology
• * Pharmacology and Drug Discovery

Background:

• * The COVID-19 pandemic, declared by the WHO in March 2020, necessitated an urgent search for effective treatments.
• * Existing drugs were evaluated for repurposing to accelerate treatment availability and reduce development costs.
• * No specific antiviral drugs or vaccines were initially available for SARS-CoV-2.

Purpose of the Study:

• * To review the initial drug repurposing candidates for COVID-19 treatment.
• * To examine the scientific evidence, public demand, and politicization surrounding these treatments.
• * To contrast evidence-based medicine with unqualified opinions during the pandemic.

Main Methods:

• * Literature review of early COVID-19 treatment research.
• * Analysis of drug repurposing strategies for SARS-CoV-2.
• * Examination of scientific discourse on hydroxychloroquine, ivermectin, and remdesivir.

Main Results:

• * Hydroxychloroquine, ivermectin, and remdesivir were identified as early repurposing candidates.
• * Conflicting scientific evidence and significant public/political influence complicated treatment decisions.
• * The pandemic highlighted challenges in distinguishing scientific evidence from public opinion.

Conclusions:

• * Drug repurposing offers a potential pathway for rapid COVID-19 treatment deployment.
• * The scientific evaluation of treatments was challenged by external pressures.
• * Distinguishing between scientific evidence and opinion is crucial for public health decisions.